Lineage Cell Therapeutics, Inc. Operating Expenses
Lineage Cell Therapeutics, Inc. (LCTX) reported Operating Expenses of $8.19 million for the 3-month period ending 2023-12-31, per its 10-K filed 2024-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-03-07
- Lineage Cell Therapeutics, Inc. operating expenses for the quarter ending 2023-12-31 was $8.19M, a 3.05% decline year-over-year.
- Lineage Cell Therapeutics, Inc. operating expenses for the quarter ending 2023-09-30 was $7.78M, a 2.89% decline year-over-year.
- Lineage Cell Therapeutics, Inc. operating expenses for the quarter ending 2023-06-30 was $8.12M, a 5.25% decline year-over-year.
- Lineage Cell Therapeutics, Inc. operating expenses for the quarter ending 2023-03-31 was $8.91M, a 22.24% decline year-over-year.
- Lineage Cell Therapeutics, Inc. operating expenses for fiscal 2023 was $33.01M, a 9.56% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. operating expenses for fiscal 2022 was $36.49M, a 29.99% decline from fiscal 2021.
- Lineage Cell Therapeutics, Inc. operating expenses for fiscal 2021 was $52.13M, a 86.91% increase from fiscal 2020.
- Lineage Cell Therapeutics, Inc. operating expenses for fiscal 2020 was $27.89M, a 33.57% decline from fiscal 2019.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $8.19M 10-K · filed 2024-03-07 | $15.98M derived: sum of 2 quarters · filed 2024-03-07 | $24.10M derived: sum of 3 quarters · filed 2024-03-07 | $33.01M 10-K · filed 2024-03-07 | ||||
| 2023-09-30 | $7.78M 10-K · filed 2024-03-07 | $15.90M derived: sum of 2 quarters · filed 2024-03-07 | $24.81M 10-Q · filed 2023-11-09 | $33.27M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2023-06-30 | $8.12M 10-K · filed 2024-03-07 | $17.03M 10-Q · filed 2023-08-10 | $25.48M derived: sum of 3 quarters · filed 2024-03-07 | $33.50M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2023-03-31 | $8.91M 10-K · filed 2024-03-07 | $17.36M derived: sum of 2 quarters · filed 2024-03-07 | $25.38M derived: sum of 3 quarters · filed 2024-03-07 | $33.95M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2022-12-31 | $8.45M 10-K · filed 2024-03-07 | $16.47M derived: sum of 2 quarters · filed 2024-03-07 | $25.04M derived: sum of 3 quarters · filed 2024-03-07 | $36.49M 10-K · filed 2024-03-07 | ||||
| 2022-09-30 | $8.01M 10-K · filed 2024-03-07 | $16.59M derived: sum of 2 quarters · filed 2024-03-07 | $28.04M 10-Q · filed 2023-11-09 | $57.24M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2022-06-30 | $8.57M 10-K · filed 2024-03-07 | $20.03M 10-Q · filed 2023-08-10 | $49.23M derived: sum of 3 quarters · filed 2024-03-07 | $57.36M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2022-03-31 | $11.46M 10-K · filed 2024-03-07 | $40.66M derived: sum of 2 quarters · filed 2024-03-07 | $48.79M derived: sum of 3 quarters · filed 2024-03-07 | $56.25M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2021-12-31 | $29.20M 10-K · filed 2023-03-09 | $37.33M derived: sum of 2 quarters · filed 2023-03-09 | $44.80M derived: sum of 3 quarters · filed 2023-03-09 | $52.13M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $8.13M 10-K · filed 2023-03-09 | $15.60M derived: sum of 2 quarters · filed 2023-03-09 | $22.92M 10-Q · filed 2022-11-10 | $29.05M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-06-30 | $7.47M 10-K · filed 2023-03-09 | $14.80M 10-Q · filed 2022-08-11 | $20.92M derived: sum of 3 quarters · filed 2023-03-09 | $28.11M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-03-31 | $7.33M 10-K · filed 2023-03-09 | $13.45M derived: sum of 2 quarters · filed 2023-03-09 | $20.65M derived: sum of 3 quarters · filed 2023-03-09 | $27.36M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2020-12-31 | $6.12M 10-K · filed 2022-03-10 | $13.32M derived: sum of 2 quarters · filed 2022-03-10 | $20.03M derived: sum of 3 quarters · filed 2022-03-10 | $27.89M 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | $7.19M 10-K · filed 2022-03-10 | $13.91M derived: sum of 2 quarters · filed 2022-03-10 | $21.77M 10-Q · filed 2021-11-10 | $29.75M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-06-30 | $6.71M 10-K · filed 2022-03-10 | $14.57M 10-Q · filed 2021-08-12 | $22.56M derived: sum of 3 quarters · filed 2022-03-10 | $31.44M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-03-31 | $7.86M 10-K · filed 2022-03-10 | $15.85M derived: sum of 2 quarters · filed 2022-03-10 | $24.72M derived: sum of 3 quarters · filed 2022-03-10 | $36.22M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2019-12-31 | $7.99M 10-K · filed 2021-03-11 | $16.86M derived: sum of 2 quarters · filed 2021-03-11 | $28.36M derived: sum of 3 quarters · filed 2021-03-11 | $41.98M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $8.88M 10-K · filed 2021-03-11 | $20.37M derived: sum of 2 quarters · filed 2021-03-11 | $33.99M 10-Q · filed 2020-11-04 | $44.80M derived: sum of 4 quarters · filed 2021-03-11 | ||||
| 2019-06-30 | $11.49M 10-K · filed 2021-03-11 | -$11.49M 10-Q · filed 2019-08-08 | $25.11M 10-Q · filed 2020-08-06 | -$25.11M 10-Q · filed 2019-08-08 | $35.93M derived: sum of 3 quarters · filed 2021-03-11 | $47.23M derived: sum of 4 quarters · filed 2021-03-11 | ||
| 2019-03-31 | $13.62M 10-K · filed 2021-03-11 | -$13.62M 10-Q · filed 2019-05-09 | $24.43M derived: sum of 2 quarters · filed 2021-03-11 | $35.74M derived: sum of 3 quarters · filed 2021-03-11 | $47.32M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-12-31 | $10.81M 10-K · filed 2020-03-12 | $22.12M derived: sum of 2 quarters · filed 2020-03-12 | $33.70M derived: sum of 3 quarters · filed 2020-03-12 | $46.48M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $11.30M 10-K · filed 2020-03-12 | $22.89M derived: sum of 2 quarters · filed 2020-03-12 | $35.56M 10-Q · filed 2019-11-12 | $46.18M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $11.59M 10-K · filed 2020-03-12 | -$24.26M 10-Q · filed 2019-08-08 | $24.26M 10-Q · filed 2018-08-02 | $34.87M derived: sum of 3 quarters · filed 2020-03-12 | $46.02M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-03-31 | $12.78M 10-K · filed 2020-03-12 | -$12.78M 10-Q · filed 2018-05-10 | $23.29M derived: sum of 2 quarters · filed 2020-03-12 | $34.44M derived: sum of 3 quarters · filed 2020-03-12 | $45.13M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | $10.51M 10-K · filed 2019-03-14 | $21.66M derived: sum of 2 quarters · filed 2019-03-14 | $32.35M derived: sum of 3 quarters · filed 2019-03-14 | $43.95M 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | $11.15M 10-K · filed 2019-03-14 | $21.84M derived: sum of 2 quarters · filed 2019-03-14 | $33.44M 10-Q · filed 2018-11-08 | $45.79M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $10.69M 10-K · filed 2019-03-14 | $22.29M 10-Q · filed 2018-08-02 | $34.65M derived: sum of 3 quarters · filed 2019-03-14 | $45.64M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $11.60M 10-K · filed 2019-03-14 | $23.95M derived: sum of 2 quarters · filed 2019-03-14 | $34.95M derived: sum of 3 quarters · filed 2019-03-14 | $50.52M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $12.36M 10-K · filed 2018-03-15 | $23.35M derived: sum of 2 quarters · filed 2018-03-15 | $38.93M derived: sum of 3 quarters · filed 2018-03-15 | $64.53M 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $11.00M 10-K · filed 2018-03-15 | $26.57M derived: sum of 2 quarters · filed 2018-03-15 | $52.18M 10-Q · filed 2017-11-09 | $75.19M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-06-30 | $15.57M 10-K · filed 2018-03-15 | $41.18M 10-Q · filed 2017-08-09 | $64.19M derived: sum of 3 quarters · filed 2018-03-15 | $83.17M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-03-31 | $25.61M 10-K · filed 2018-03-15 | $48.62M derived: sum of 2 quarters · filed 2018-03-15 | $67.60M derived: sum of 3 quarters · filed 2018-03-15 | $82.84M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-12-31 | $23.01M 10-K · filed 2017-03-16 | $23.01M 10-K · filed 2016-03-15 | $41.99M derived: sum of 2 quarters · filed 2017-03-16 | $57.24M derived: sum of 3 quarters · filed 2017-03-16 | $71.74M 10-K · filed 2018-03-15 | |||
| 2015-09-30 | $18.98M 10-K · filed 2017-03-16 | $34.22M derived: sum of 2 quarters · filed 2017-03-16 | $48.73M 10-Q · filed 2016-11-04 | $64.79M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $15.24M 10-K · filed 2017-03-16 | $29.75M 10-Q · filed 2016-08-09 | $45.82M derived: sum of 3 quarters · filed 2017-03-16 | $58.91M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $14.50M 10-K · filed 2017-03-16 | $14.50M 10-Q · filed 2015-05-08 | $30.57M derived: sum of 2 quarters · filed 2017-03-16 | $43.67M derived: sum of 3 quarters · filed 2017-03-16 | $57.59M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $16.07M 10-K · filed 2016-03-15 | $16.07M 10-K · filed 2015-03-11 | $29.17M derived: sum of 2 quarters · filed 2016-03-15 | $43.08M derived: sum of 3 quarters · filed 2016-03-15 | $55.09M 10-K · filed 2017-03-16 | $55.09M 10-K · filed 2015-03-11 | ||
| 2014-09-30 | $13.10M 10-K · filed 2016-03-15 | $13.10M 10-Q · filed 2014-11-07 | $27.02M derived: sum of 2 quarters · filed 2016-03-15 | $39.03M 10-Q · filed 2015-11-09 | $39.03M 10-Q · filed 2014-11-07 | $52.59M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $13.92M 10-K · filed 2016-03-15 | $13.92M 10-Q · filed 2014-08-11 | $25.97M 10-Q · filed 2015-08-10 | $25.97M 10-Q · filed 2014-08-11 | $39.49M derived: sum of 3 quarters · filed 2016-03-15 | $50.20M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | $12.07M 10-K · filed 2016-03-15 | $12.07M 10-Q · filed 2014-05-12 | $25.58M derived: sum of 2 quarters · filed 2016-03-15 | $36.29M derived: sum of 3 quarters · filed 2016-03-15 | $45.44M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2013-12-31 | $13.50M 10-K · filed 2015-03-11 | $24.21M derived: sum of 2 quarters · filed 2015-03-11 | $33.37M derived: sum of 3 quarters · filed 2015-03-11 | $59.63M 10-K · filed 2016-03-15 | $59.63M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $10.71M 10-K · filed 2015-03-11 | $19.86M derived: sum of 2 quarters · filed 2015-03-11 | $28.66M 10-Q · filed 2014-11-07 | $36.80M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-06-30 | $9.15M 10-K · filed 2015-03-11 | $17.98M 10-Q · filed 2014-08-11 | $26.09M derived: sum of 3 quarters · filed 2015-03-11 | $32.87M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-03-31 | $8.81M 10-K · filed 2015-03-11 | $16.94M derived: sum of 2 quarters · filed 2015-03-11 | $23.72M derived: sum of 3 quarters · filed 2015-03-11 | $30.75M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2012-12-31 | $8.12M 10-K · filed 2014-03-17 | $14.91M derived: sum of 2 quarters · filed 2014-03-17 | $21.93M derived: sum of 3 quarters · filed 2014-03-17 | $28.48M 10-K · filed 2015-03-11 | ||||
| 2012-09-30 | $6.78M 10-K · filed 2014-03-17 | $13.81M derived: sum of 2 quarters · filed 2014-03-17 | $20.36M 10-Q · filed 2013-11-12 | $27.44M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-06-30 | $7.03M 10-K · filed 2014-03-17 | $13.58M 10-Q · filed 2013-08-09 | $20.66M derived: sum of 3 quarters · filed 2014-03-17 | $26.03M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-03-31 | $6.55M 10-K · filed 2014-03-17 | $13.63M derived: sum of 2 quarters · filed 2014-03-17 | $19.00M derived: sum of 3 quarters · filed 2014-03-17 | $24.74M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2011-12-31 | $7.08M 10-K · filed 2013-03-18 | $12.45M derived: sum of 2 quarters · filed 2013-03-18 | $18.19M derived: sum of 3 quarters · filed 2013-03-18 | $23.04M 10-K · filed 2014-03-17 | ||||
| 2011-09-30 | $5.38M 10-K · filed 2013-03-18 | -$5.38M 10-Q · filed 2011-11-08 | $11.11M derived: sum of 2 quarters · filed 2013-03-18 | $15.95M 10-Q · filed 2012-11-09 | -$15.95M 10-Q · filed 2011-11-08 | $37.85M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-06-30 | $5.74M 10-K · filed 2013-03-18 | $10.59M 10-Q · filed 2012-08-09 | $32.48M derived: sum of 3 quarters · filed 2013-03-18 | $29.20M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-03-31 | $4.85M 10-K · filed 2013-03-18 | $26.74M derived: sum of 2 quarters · filed 2013-03-18 | $23.47M derived: sum of 3 quarters · filed 2013-03-18 | $26.46M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2010-12-31 | $21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $18.62M derived: sum of 2 quarters · filed 2013-03-18 | $21.61M derived: sum of 3 quarters · filed 2013-03-18 | $13.53M 10-K · filed 2013-03-18 | ||||
| 2010-09-30 | -$3.27M 10-Q · filed 2011-11-08 | -$277.29K derived: sum of 2 quarters · filed 2011-11-08 | -$8.36M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $3.00M 10-Q · filed 2011-08-09 | $5.09M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $5.45M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |